Hamill John P 4
4 · PharmaNet Development Group Inc · Filed Mar 24, 2009
Insider Transaction Report
Form 4
Hamill John P
EVP and CFO
Transactions
- Disposition to Issuer
OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001
2009-03-20−3,571→ 0 totalExercise: $13.86→ COMMON STOCK, PAR VALUE $.001 (3,571 underlying) - Disposition from Tender
Common Stock, Par value $.001
2009-03-20$5.00/sh−45,396$226,980→ 0 total - Disposition to Issuer
OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001
2009-03-20−4,533→ 0 totalExercise: $26.91→ COMMON STOCK, PAR VALUE $.001 (4,533 underlying) - Disposition to Issuer
OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001
2009-03-20−4,841→ 0 totalExercise: $29.47→ COMMON STOCK, PAR VALUE $.001 (4,841 underlying) - Disposition to Issuer
OPTIONS TO PURCHASE COMMON STOCK, PAR VALUE $.001
2009-03-20−895→ 0 totalExercise: $40.39→ COMMON STOCK, PAR VALUE $.001 (895 underlying)
Footnotes (2)
- [F1]Of such amount, 16,214 shares automatically vested and were paid for in connection with the change in control which occurred upon the acceptance of shares pursuant to the tender offer (the "Offer") which was launched in connection with the Agreement and Plan of Merger dated February 3, 2009 by and among JLL PharmaNet Holdings, LLC ("Parent"), PDGI Acquisition Corp. ("Purchaser") and PharmaNet ("PharmaNet"). Mr. Hamill has not immediately received the funds associated with this vesting pursuant to Internal Revenue Code 409A. On March 20, 2009, all shares which were tendered by the filing person in connection with the Offer, were accepted by the Purchaser. Any shares which were not tendered by the filing person will be cashed out at the closing of the Merger.
- [F2]Such options were canceled in connection with the Merger in exchange for the right to receive the difference between the merger consideration of $5.00 per share and the options exercise price.